Literature DB >> 8894583

In vitro activity of trovafloxacin in combination with ceftazidime, meropenem, and amikacin.

D Milatovic1, C Wallrauch.   

Abstract

The in vitro activity of trovafloxacin alone and in combination with ceftazidime, meropenem, and amikacin was studied by determining the minimal inhibitory concentrations (MICs) for 111 gram-negative and 71 gram-positive bacteria. In addition, the synergy of these combinations against 46 strains of gram-negative and gram-positive organisms was studied by checkerboard titration and time-kill kinetics. Trovafloxacin exhibited excellent in vitro activity against all strains tested. Synergism was observed in 17% of the gram-negative strains and in 32% of the gram-positive strains. No antagonism was observed with any of the combinations tested.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8894583     DOI: 10.1007/bf01691162

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  14 in total

1.  Ciprofloxacin, azlocillin, ceftizoxime and amikacin alone and in combination against gram-negative bacilli in an infected chamber model.

Authors:  D M Bamberger; L R Peterson; D N Gerding; J A Moody; C E Fasching
Journal:  J Antimicrob Chemother       Date:  1986-07       Impact factor: 5.790

2.  In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.

Authors:  G M Eliopoulos; K Klimm; C T Eliopoulos; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

3.  In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial.

Authors:  T D Gootz; K E Brighty; M R Anderson; B J Schmieder; S L Haskell; J A Sutcliffe; M J Castaldi; P R McGuirk
Journal:  Diagn Microbiol Infect Dis       Date:  1994-08       Impact factor: 2.803

Review 4.  Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: clinical significance and therapeutic approaches.

Authors:  P Ball
Journal:  J Antimicrob Chemother       Date:  1990-12       Impact factor: 5.790

5.  Evaluation of ciprofloxacin's synergism with other agents by multiple in vitro methods.

Authors:  J A Moody; D N Gerding; L R Peterson
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

6.  In vitro activity of the new fluoroquinolone CP-99,219.

Authors:  H C Neu; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

7.  In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone.

Authors:  B B Gooding; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

8.  Comprehensive evaluation of ciprofloxacin-aminoglycoside combinations against Enterobacteriaceae and Pseudomonas aeruginosa strains.

Authors:  I Haller
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

9.  Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

10.  Antimicrobial activity of netilmicin in comparison with gentamicin, sisomicin, tobramycin, and amikacin and their resistance patterns.

Authors:  I Braveny; J Voeckl; K Machka
Journal:  Arzneimittelforschung       Date:  1980
View more
  2 in total

Review 1.  Combination therapy for treatment of infections with gram-negative bacteria.

Authors:  Pranita D Tamma; Sara E Cosgrove; Lisa L Maragakis
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

Review 2.  An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.

Authors:  Anand Kumar
Journal:  Virulence       Date:  2013-11-01       Impact factor: 5.882

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.